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Background: Previous studies have pointed out the role of dickkopf-related protein 1 (DKK 1) — Wnt inhibitor, which is essential 
for osteoblast functioning, in the development of osteolytic lesions in multiple myeloma (MM). Aim: To assess the DKK 1 expres-
sion displayed by myeloma cells in bone marrow trephine biopsies of patients with and without osteolytic lesions, and in different 
malignancy grades of the disease. Methods: The expression level of DKK 1 was assessed immunohistochemically in bone marrow 
of 49 MM patients presented with and without osteolytic lesions (the 1st and the 2nd group, respectively). Results: Levels of weak, 
moderate, and strong DKK 1 expression were distributed — as 43.33, 27.78 and 25.56%, and 63.91, 18.80, and 1.50%, respectively 
when evaluating the samples obtained from the 1st group and 2nd group. Statistically significant differences were found when the 
levels of DKK 1 expression in the 1st and the 2nd group were compared (χ2 = 51; df = 3; p < 0.001). Conclusions: DKK 1 contributes 
to the development of osteolytic lesions in MM. The present study provides morphological evidence that inhibition in Wnt signaling 
may lead to bone damage observed in the advanced stage of the disease.
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A growing �ody of evidence suggests an increase 
in the incidence of multiple myeloma �MM�. It accounts 
for approximately 1�% of all hematological neoplasms 
and is the second most frequent hematological 
malignancy [1�3]. According to WHO ��1� data� 
1�9�9�� MM cases were diagnosed in ��1� causing 
1�6�1�� deaths worldwide.
One of the most common MM complications 
is a �one disease frequently presented with osteolytic 
lesions [�� �]. The etiology of osteolytic �one damage 
in MM is not fully understood �ut seems to involve 
interaction �etween myeloma cells and �one marrow 
microenvironment [6� 7]. It has �een recognized that 
receptor activator of nuclear factor kappa β ligand 
and osteoprotegerin produced �y the �one marrow 
microenvironment and osteo�lasts are locally acting 
factors of osteoclast regulation [�� 9].
R e c e n t l y�  t h e  ro l e  o f  d i c k k o p f - re l a t e d 
protein 1 ��KK 1� has come into focus as a target for 
the immunotherapy of MM [1�]. The Wnt signaling 
pathway is an important regulator of the growth and 
differentiation of osteo�lasts� and �KK 1 is a Wnt 
signaling pathway inhi�itor [11]. Previous studies 
have suggested that a shift in the receptor activator 
of nuclear factor kappa β ligand/osteoprotegerin levels 
found in MM su�jects is mediated �y disruption of Wnt 
signaling in osteo�lasts and their precursors� thus pro-
viding a rationale for the development of therapeutic 
strategies that target �KK 1 in the disease.
Furthermore� other studies have demonstrated 
�KK 1 overexpression in MM cells� and especially 
in patients with the severe �one destruction [1�]. 
Osteo�last inhi�ition and osteoclast activation 
�y �KK 1 have �een shown in several experimental 
studies and preclinical trials suggesting that this Wnt 
inhi�itor is the driving force in osteolytic �one damage.
The purpose of this study was to assess the 
�KK 1 expression displayed �y myeloma cells in �one 
marrow trephine �iopsies of patients with and with-
out osteolytic lesions� and in different malignancy 
grades of the disease suggesting the contri�ution 
of �KK 1 to �one damage demonstrated in MM.
MATERIALS AND METHODS
Patients. Forty-nine patients recruited from Riga 
East University Hospital� Oncology Center of Latvia� 
with primary diagnosed MM were enrolled in the 
study �etween June ��1� and June ��16. The study 
was approved �y the Ethical Committee of Riga 
Stradins University� and it was conducted according 
to the �eclaration of Helsinki. Of �9 MM patients� 
�1% were women� and �9% men. The median age 
was 67.3� years� with the youngest patient — 33 years 
and the oldest — �6 years �S� 11.9�. All MM su�jects 
fulfilled relevant International Myeloma Working Group 
criteria for the disease. Salmon — �urie staging sys-
tem and the International Staging System for clinical 
classification of MM were used on standardized clinical 
data that were collected from medical records. All pa-
tients were su�divided into two groups — su�jects with 
�the 1st group� and without �the �nd group� osteolytic 
lesions� accordingly. The average age of MM su�jects 
of the 1st group was 6�.1� years �S� 13.�� whereas 
the �nd group — 7�.7� years �S� �.��.
Submitted: May 17, 2020. 
*Correspondence: E-mail: dauzina@inbox.lv 




��6 Experimental Oncology ��� �������� ���� ��ecem�er�
Conventional radiography� computed tomography� 
and magnetic resonance imaging were used for the 
confirmation of multiple destructive lytic �one lesions� 
as well as severe compression fractures of the verte-
�rae or ri�s. According to the International Myeloma 
Working Group criteria� > 1 focal lesions on magnetic 
resonance imaging a�out � mm or greater in size was 
considered a true a�normal.
Light microscopy and immunohistochemistry. 
Bone marrow trephine �iopsy specimens �n = �9� 
were o�tained routinely from the posterior iliac crests 
of patients with primary diagnosed MM. Two series 
of histological sections of ��� μm were cut from 1�% 
formalin-fixed� paraffin-em�edded �iopsy samples� 
and mounted on SuperFrost Plus slides �Germany 
Menzel Gm�H� Germany� slides for routine histopatho-
logical and immunohistochemical evaluation. Before 
immunostaining� deparaffinization and hydration were 
done in xylene and graded alcohol to distilled water. 
�uring hydration� a �-min �locking for endogeneous 
peroxidase is done with �.3% �v/v� H�O� in 9�% etha-
nol. Heat-induced epitope retrieval was accomplished 
with the sections immersed in 1� mM sodium citrate 
�uffer� pH 6.�� at 1�� °C for � min in a vapor lock.
Immunohistochemistry was performed conven-
tionally using polyclonal ra��it anti-human �KK 1 an-
ti�ody �Sigma Life Science� Inc.� Sigma-Aldrich� USA� 
HPA�1�99�� 1:��� raised against �KK 1 precursor 
recom�inant protein epitope signature tag. The am-
plification of the primary anti�ody and visualization 
of reaction products was performed applying the 
Hi�ef �etection HRP Polymer system and diami-
no�enzidine tetrahydrochloride su�strate kit �Cell 
Marque� USA�. The sections were counterstained 
with Mayer’s hematoxylin� washed� mounted� and 
covered with coverslips. Immunohistochemical con-
trols included the omission of the primary anti�ody. 
Sections were photographed �y a Leitz �MRB �right-
field microscope using a �FC ���C digital camera and 
a Glissando Slide Scanner �O�jective Imaging Ltd.� UK� 
�.� μm/pixel resolution with ��× o�jective� �.�7� μm/
pixel resolution with ��× o�jective. The assessment 
of conventional histopathology and immunostaining 
was performed �y two independent o�servers �linded 
to clinicopathological data.
Assessment of histopathology and immu-
nohistochemistry findings. Routinely processed 
specimens were evaluated applying hematoxylin 
and eosin staining and classified according to Bartl 
grading system: Marschalko type� small cell� cleaved� 
polymorphous� asynchronous� and plasma�lastic. 
These six histopathological types were stratified into 
three malignancy grades: low �Marschalko and small 
cell types�� intermediate �cleaved� polymorphous� and 
asynchronous types�� and high �plasma�lastic type� 
grade MM [13].
Cells that were la�eled with �KK 1 anti�ody and 
displayed �rown reaction products were considered 
as immunopositive. The levels of immunopositivity for 
�KK 1 were defined semiquantitatively and graded into 
four groups: no cells stained ��%�; weak staining: few 
cells stained �1�1�%�; moderate: a moderate num�er 
of cells stained �11���%�� and strong: the majority 
of cells stained ��1�1��%�. 
Statistical data analysis. Statistical analysis was 
performed using the SPSS system �version �3.��. 
�escriptive statistics were used to analyze the clinical 
and la�oratory parameters of the study groups. The 
quantitative data were expressed as means ± standard 
deviation� whereas categorical parameters were ex-
pressed as frequencies and percentages. Correlation 
�etween �KK 1 antigen expression and clinical data 
was studied �y χ� statistics. P values of < �.�� were 
considered significant.
RESULTS
Patients’ characteristics. We found that among 
patients with osteolytic lesions� MM stage IIA �9�.3%� 
was the most common whereas in patients without 
osteolytic lesions — IA ���.�%�. Radiologically� 17 pa-
tients �3�.7%� were presented without any detecta�le 
�one lesion� whereas �� ��7.1%� demonstrated severe 
MM-associated �one lesions. One-fifth �1�.�%� of os-
teolytic patients revealed hypercalcemia� and it was 
demonstrated significantly more often �p < 0.05� when 
compared to the �nd group.
MM malignancy grades. By summing up� low-
grade malignancy MM was confirmed in �� ��7.1�%� 
of cases — 1� �36.73%� and 1� ���.��%�� in the 1st 
and �nd group� respectively when the intermediate 
grade MM — in 1� ���.�7%� of cases — 7 �1�.�9%� 
and 7 �1�.�9%�� in the 1st and �nd group� respectively. 
Finally� the high-grade malignancy MM was diagnosed 
in 7 �1�.�9%� of cases presented exclusively in su�-
jects with osteolytic damage �Ta�le 1�.
Table 1. Plasma cell malignancy grade in MM patients groups
MM group Plasma cell malignancy gradeLow Intermediate High
1st group 18 (36.73%) 7 (14.29%) 7 (14.29%)
2nd group 10 (20.40%) 7 (14.29%) -
Immunohistochemistry. When studying the his-
topathological appearance of specimens in MM su�-
jects� and the contri�ution of �KK 1 �y immunohisto-
chemistry� we found that levels of the antigen expres-
sion greatly varied from almost nil to weak� moderate 
and strong �Ta�le ��. We found statistically significant 
differences when the levels of �KK 1 expression in the 
1st and the �nd group were compared �χ� = �1; df = 3; 
p < 0.001�. In a group of patients with osteolytic le-
sions� less than one-half of regions of interest found 
in the samples estimated ��3.33%� revealed weak 
�KK 1 expression. Simultaneously� more frequent 
occurrence of the weak antigen expression �63.91%� 
was demonstrated in the samples without osteolytic 
lesions. The levels of moderate and strong �KK 1 ex-
pression were equally distri�uted — �7.7�% and 
��.�6%� respectively� when evaluating the samples 
o�tained from the 1st group. By contrast� the strong 
expression of the antigen was very low in the �nd group 
and comprised 1.�% only. Furthermore� we found 
statistically significant differences �etween �KK 1 an-
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tigen expression levels in histologically graded types 
�p < 0.001�. Almost two-thirds �7�.66%� and ��.7�% 
of the regions of interest evaluated were presented 
with weak �KK 1 expression in the low-grade and 
intermediate-grade MM� respectively. Simultaneously� 
the moderate� and� especially� strong expression of the 
antigen was common in intermediate and high-grade 
MM — �3.3� and �9.�6%� respectively �Ta�le 3�.








The 1st group 1 (3.33%) 13 (43.33%) 9 (27.78%) 8 (25.56%)
The 2nd group 3 (15.79%) 12 (63.91%) 2 (18.80%) 1 (1.50%)













Low 2 (8.38%) 20 (70.66%) 5 (16.17%) 1 (4.79%)
Intermediate 0 6 (40.78%) 5 (35.92%) 3 (23.30%)
High 0 0 3 (40.74%) 4 (59.26%)
In the case of intermediate-grade MM� represented 
�y three morphological patterns� we found hetero-
geneity of �KK 1 expression displayed �y malignant 
plasma cells reflecting the extent of secretory func-
tion and osteolytic �one lesions �Figure� a–d�. Finally� 
we did not find any statistically significant differences 
in �KK 1 expression when clinically defined MM stages 
were evaluated.
DISCUSSION
MM �eing severe and largely incura�le B-cells 
malignancy accumulating primarily in the �one mar-
row represents a�out 1.�% of all cancers and a�out 
1�% of hematological neoplasia [1�]. Osteolytic �one 
lesions resulting from the upraised activity of osteo-
clasts and decreased rates of osteogenesis �y osteo-
�lasts commonly develop at an advanced stage of the 
disease [1�� 16]. It has �een shown that more than ��% 
of MM patients develop destructive �one lesions and 
6�% are presented with fractures during the disease 
course [17� 1�]. Previous studies have reported the 
success of MM treatment and normalization of �one 
remodeling� reducing serum �KK 1 levels [19]. �KK1� 
which is expressed �y osteo�lasts and �one marrow 
stromal cells� has �een shown to act as an antagonist 
of the Wnt signaling pathway resulting in inhi�ition 
of osteo�lasts differentiation and new �one forma-
tion [6� ����3]. Furthermore� the sustained high levels 
of �KK 1 in the �one marrow of MM su�jects have 
�een shown to cause a loss in the via�ility of osteo�last 
precursors as well [��]. The Wnt signal is diminished 
when �KK 1 protein �inds to the LPR�/6 receptor and 
coreceptor� Kremen-1/�� thus promoting internaliza-
tion of the receptor complex at the cell surface [��]. 
The authors have demonstrated that �KK 1 impairs 
local �one formation along with the regulation of sys-
temic �one mass through Wnt signaling.
In the present study� we have estimated the lev-
els of the �KK 1 expression displayed in different 
malignancy grades of the disease suggesting on the 
contri�ution of �KK 1 to �one damage demonstrated 
in MM� assessed morphological patterns of plasma 
cells using �one marrow trephine �iopsies o�tained 
from �9 MM su�jects presented with and without 
osteolytic lesions; investigated the fine structure 
of malignant plasma cells.
Our o�servations revealed moderate and strong 
�KK 1 expression appearing in the samples of os-
teolytic patients with osteolytic lesions significantly 
more often when compared to the samples o�tained 
from patients without osteolytic �one lesions. These 
results are in agreement with those �y Kristensen 
et al. [�] who demonstrated significantly higher lev-
els of �KK1 mRNAs expressed in MM samples with 
advanced osteolytic lesions. Simultaneously� our 
results show that the levels of �KK 1 expression differ 
significantly when low� intermediate� and high plasma 
cell malignancy grades are compared.
Other authors have demonstrated that anti-
�KK 1 treatment increased �one formation rate 
�y ��% and mineralizing surface �y ��% and have 
suggested that restoring osteo�last differentiation can 
prevent the development of osteolytic �one lesions 
in MM� offering an effective therapeutic approach 
to treating this clinically important aspect of the dis-
ease [1�]. Furthermore� clinically tested neutralizing 
anti-�KK 1 monoclonal anti�ody BHQ��� has demon-
strated �eneficial effect resulted in an increase in �one 
mass found in MM su�jects [�].
The present study provides immunohistochemi-
cal evidence that inhi�ition in Wnt signaling may lead 
to �one damage o�served in the advanced stage 
of MM.
Concluding� we may suggest that the assessment 
of �one marrow �iopsy findings remains an essential 
part of the diagnostic evaluation of MM. Osteo-
lytic �one lesions are the most common complication 
of MM. Estimation of �KK 1 in routinely o�tained �iop-
sies may offer an additional approach to interpreting 
this clinically important aspect of the disease.
Figure. The greatly varying expression of �KK 1 is demonstrated 
in intermediate-grade MM and evaluated as weak �panel a�� and 
moderate to strong �panel b–d�. The malignant cells demon-
strate notched� cleaved� or even convoluted nuclei of varia�le 
size� nucleoli� often prominent and centrally located. Marked 
cellular polymorphism and multinuclearity� some giant plasma 
cells are present as well. Magnification: a: × ���; �: × ���; 
c: × ���; d: × ���
��� Experimental Oncology ��� �������� ���� ��ecem�er�
REFERENCES
1. Gavriatopoulou M, Fotiou D, Ntanasis-Stathopoulos I, et al. 
How I treat elderly patients with plasma cell dyscrasias. Aging 
2018; 10: 4248–68.
2. Spaan I, Raymakers RA, van de Stolpe A, et al. Wnt 
signaling in multiple myeloma: a central player in disease with 
therapeutic potential. J Hematol Oncol 2018; 11: 67.
3. Terpos E, Kostopoulos IV, Kastritis E, et al. Impact 
of minimal residual disease detection by next-generation 
flow cytometry in multiple myeloma patients with sustained 
complete remission after frontline therapy. Hemasphere 2019; 
3: e300.
4. Hata H. Bone lesions and macrophage inflammatory 
protein-1 alpha (MIP-1a) in human multiple myeloma. Leuk 
Lymphoma 2005; 46: 967–72.
5. Sezer O. Myeloma bone disease: recent advances in bio-
logy, diagnosis, and treatment. Oncologist 2009; 14: 276–83.
6. Qiang Y, Chen Y, Stephens O, et al. Myeloma-derived 
Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and 
RANKL production by osteoblasts: a potential mechanism 
underlying osteolytic bone lesions in multiple myeloma. Blood 
2008; 112: 196–207.
7. Abe M. Targeting the interplay between myeloma cells 
and the bone marrow microenvironment in myeloma. Int 
J Hematol 2011; 94: 334–43.
8. Kristensen I, Christensen J, Lyng M, et al. Expression 
of osteoblast and osteoclast regulatory genes in the bone 
marrow microenvironment in multiple myeloma: only up-
regulation of Wnt inhibitors SFRP3 and DKK1 is associated 
with lytic bone disease. Leuk Lymphoma 2014; 55: 911–9.
9. Roodman G. Pathogenesis of myeloma bone disease. 
Leukemia 2009; 23: 435–41.
10. Liu T, Wu Y, Niu T. Human DKK1 and human 
HSP70 fusion DNA vaccine induces an effective anti-tumor 
efficacy in murine multiple myeloma. Oncotarget 2018; 
9: 178–91.
11. Ray S, Khassawna T, Sommer U, et al. Differences in ex-
pression of Wnt antagonist Dkk1 in healthy versus pathological 
bone samples. J Microsc 2016; 265: 111–20.
12. Heath D, Chantry A, Buckle C, et al. Inhibiting Dick-
kopf-1 (DKK 1) removes suppression of bone formation and 
prevents the development of osteolytic bone disease in multiple 
myeloma. J Bone Miner Res 2009; 24: 425–36.
13. Bartl R, Frisch B, Fateh-Moghadam A, et al. Histologic 
classification and staging of multiple myeloma. A retrospective 
and prospective study of 674 cases. Am J Clin Pathol 1987; 
87: 342–55.
14. Wajs J, Sawicki W. The morphology of myeloma cells 
changes with progression of the disease. Contemp Oncol 
(Pozn) 2013; 17: 272–5.
15. Berenson JR. Therapeutic options in the management 
of myeloma bone disease. Semin Oncol 2010; 37: 20–9.
16. Terpos E, Christoulas D, Gavriatopoulou M, Dimopou-
los MA. Mechanisms of bone destruction in multiple myeloma. 
Eur J Cancer Care 2017; 26: doi: 10.1111/ecc.12761.
17. Terpos E, Berenson J, Cook R, et al. Prognostic variables 
for survival and skeletal complications in patients with multiple 
myeloma osteolytic bone disease. Leukemia 2010; 24: 1043–9.
18. Hameed A, Brady J, Dowling P, et al. Bone disease 
in multiple myeloma: pathophysiology and management. 
Cancer Growth Metast 2014; 7: 33–42.
19. Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, 
et al. Pathogenesis of bone disease in multiple myeloma: from 
bench to bedside. Blood Cancer J. 2018; 8: 7.
20. Ribourtout B, Zandecki M. Plasma cell morphology 
in multiple myeloma and related disorders. Morphologie. 2015.
21. Koduri PR, Gowrishankar S, Malladi VK. Variant 
morphology in multiple myeloma. Indian J Hematol Blood 
Transfus 2014; 30: 86–7.
22. Blom J, Hansen OP, Mansa B. The ultrastructure 
of bone marrow plasma cells obtained from patients with 
multiple myeloma during the clinical course of the disease. 
Acta Path Microbiol Scand 1980; 88: 25–39.
23. van Marion AMW, Lokhorst HM, van den Tweel JG. Pa-
thology of multiple myeloma. Curr Diagn Pathol 2003; 9: 322–7.
24. Tian E, Zhan F, Walker R, et al. The role of the 
Wnt-Signaling Antagonist DKK1 in the development of os-
teolytic lesions in multiple myeloma. N Engl J Med 2003; 
349: 2483–94.
25. Diarra D, Stolina M, Polzer K, et al. Dick-
kopf-1 is a master regulator of joint remodeling. Nature Med 
2007; 13: 156–63.
Copyright © Experimental Oncology, 2020
